



INVESTOR IN PEOPLE

REC'D 31 JAN 2005

WIPO

PCT


The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



*R. Mahoney*

Signed

Dated 11 January 2005

**PRIORITY  
DOCUMENT**

SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)



# Patents Form 1/77

Patents Act 1977  
(Rule 16)

- 6 JUL 2004

The  
**Patent  
Office**

0415097-5  
**1/77**  
06 JUL 04 909080-3 002/06  
P01/7700 0.00-0415097.5 CHECKED

## Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet, from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road  
Newport  
South Wales NP10 8QQ

1. Your reference JED1258

2. Patent application number  
(The Patent Office will fill in this part)

0415097.5

3. Full name, address and postcode of the or of each applicant (underline all surnames)

Basant Kumar PURI  
63 Caraway Road  
Fulbourn  
Cambridge  
CB1 5DU

Patent Office  
S  
- 6 JUL 2004  
received

Patents ADP number (if you know it)

08781460001

If the applicant is a corporate body, give the country/state of its incorporation

4. Title of the invention

FORMULATION CONTAINING A CARBOXYLIC ACID  
OR AN ESTER THEREOF

5. Name of your agent (if you have one)

Barker Brettell

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

St John's Innovation Centre  
Cowley Road  
Cambridge  
CB4 0WS

Patents ADP number (if you know it)

7442494002

07442494004

6. Priority: Complete this section if you are declaring priority from one or more earlier patent applications, filed in the last 12 months.

Country

Priority application number  
(if you know it)

Date of Filing  
(day/month/year)

GB

0330206.4

31 December  
2003

7. Divisionals, etc: Complete this section only if this application is a divisional application or resulted from an entitlement dispute (see note f)

Number of earlier application

Date of filing  
(day/month/year)

8. Is a Patents Form 7/77 (Statement of inventorship and of right to grant of a patent) required in support of this request? Answer 'Yes' if:  
a) any applicant named in part 3 is not an inventor, or  
b) there is an inventor who is not named as an applicant, or  
c) any named applicant is a corporate body.  
Otherwise answer NO (See note(d))

Patents Form 1/77

## Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form.  
Do not count copies of the same document
- Continuation sheets of this form -

Description 14 + 14

Claim(s) 8 + 8

Abstract -

Drawing(s) -

10. If you are also filing any of the following, state how many against each item.
- Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination one  
(*Patents Form 9/77*)

Request for substantive examination  
(*Patents Form 10/77*)

Any other documents  
(*please specify*)

11. I/We request the grant of a patent on the basis of this application.

Signature *Barker Brettell* Date

**Barker Brettell**

05 July 2004

12. Name and daytime telephone number of person to contact in the United Kingdom

Toby Gosnall

Tel: 01223 411355

### Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

### Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 01645 500505
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

# FORMATION CONTAINING A CARBOXYLIC ACID OR AN ESTER THEREOF

This invention relates to a formulation comprising eicosapentaenoic acid,  
5 or an ester thereof, and a triterpene, or an ester thereof, and to its use in  
the treatment of, or manufacture of a medicament for the treatment of, a  
number of disorders. The formulation also has cosmetic uses. The  
invention also provides a method for the preparation of a formulation to  
be an orally administered or a method for the preparation of a formulation  
10 to be topically administered.

The present invention provides a formulation comprising:

- (a) eicosapentaenoic acid or an ester thereof; and
- 15 (b) a triterpene or an ester thereof.

Eicosapentaenoic acid can be extracted in a natural form from the oil of  
fish, in particular from so-called 'oily fish' such as sardines and salmon.  
Alternatively, eicosapentaenoic acid can be synthesised, for example ethyl  
20 eicosapentaenoic acid. Esters of eicosapentaenoic acid may be naturally  
occurring or synthesised. The formulation of the present invention may  
contain natural eicosapentaenoic acid (such as the free fatty acid),  
synthetic eicosapentaenoic acid, a naturally occurring ester of  
eicosapentaenoic acid or a synthetic ester of eicosapentaenoic acid, or a  
25 combination thereof.

Triterpenes refer to a family of naturally occurring compounds which may  
also be referred to as triterpenoids. The formulation of the invention may  
comprise a naturally occurring triterpene, a synthetic triterpene, a  
30 naturally occurring ester of a triterpene or a synthetic ester of a  
triterpene, or a combination thereof. Preferably the triterpene is a 3-O-

trans caffeoyl derivative of betulinic acid, morolic acid or oleanolic acid, faradiol-*O*-laurate, faradiol-*O*-palmitate or faradiol-*O*-myristate. Naturally occurring triterpenes can be isolated from a variety of plants including the flower heads of marigolds (*Calendula officinalis*), *Zygophyllum eichwaldii*, *Carthamus lanatus*, *Oenothera bienni* (evening primrose) or *Pyrus comminus*.

The formulation may comprise up to 99% w/w of eicosapentaenoic acid or an ester thereof. Alternatively the formulation may comprise up to 99% w/w of triterpene or an ester thereof. The formulation may comprise up to 50% w/w of eicosapentaenoic acid or an ester thereof. The formulation may comprise up to 50% w/w of triterpene or an ester thereof. The formulation may comprise up to 70% w/w of eicosapentaenoic acid or an ester thereof, more preferably of 20 to 40% w/w, and 1 to 30% w/w of a triterpene or an ester thereof.

The amount of eicosapentaenoic acid or synthetic ester thereof, and triterpene or synthetic ester thereof, required to achieve the desired therapeutic or cosmetic effect will, of course, vary depending of the compounds used, the route of administration and the disorder or condition to be treated.

Preferably the formulation comprises eicosapentaenoic acid or an ester thereof, and a triterpene or an ester thereof in a pharmaceutically acceptable form.

The formulation may also comprise a pharmaceutical carrier, diluent or excipient.

The formulation may also comprise one or more of a lubricant, a flavouring, a taste masking agent, a fragrance and a preservative.

Formulations containing eicosapentaenoic acid or an ester thereof, and a triterpene or an ester thereof, may also include other compounds for co-administration. In one embodiment such compounds may include  
5 gamma-linolenic acid and docosahexaenoic acid. In an alternative embodiment the formulation does not contain the compound docosahexaenoic acid. It is considered that in some circumstances docosahexaenoic acid can inhibit some of the benefits of eicosapentaenoic acid or an ester thereof. Known compositions containing eicosapentaenoic  
10 acid also contain docosahexaenoic acid.

The formulation comprising eicosapentaenoic acid or an ester thereof, and a triterpene or an ester thereof, may be used to treat a variety of physiological and disease states including rheumatoid arthritis,  
15 osteoarthritis, back-ache, psoriasis, pre-menstrual syndrome, bacterial infections, viral infections, fatigue, such as chronic fatigue syndrome, insomnia, anxiety, obesity, influenza, diabetes mellitus, alcoholism, cancer, neurological disorders such as multiple sclerosis, epilepsy, tardive dyskinesia and choreiform disorders such as Huntington's disease,  
20 psychiatric disorders such as depression and attention-deficit/hyperactivity disorder, cardiovascular disorders such as hyperlipidemia and high blood pressure, dermatological disorders such as eczema and atopic dermatitis, respiratory disorders, learning disabilities and ageing.

25

The formulation comprising eicosapentaenoic acid or an ester thereof, and a triterpene or an ester thereof, may be administered orally.

The formulation may be administered orally as a liquid, a paste, a tablet  
30 or a capsule.

The oral formulation may be prepared as an inert porous matrix tablet which is obtained by mixing the eicosapentaenoic acid or an ester thereof, and a triterpene or an ester thereof, with waxes or water insoluble polymers and with fillers and binders. Paraffin, polyvinylchloride, 5 ethylcellulose, stearyl alcohol, cetyl alcohol, carnauba wax, polyethylene, polyvinyl acetate, polymethyl methacrylate could be used as suitable diffusion retarding compounds. Other excipients used in the preparations of such tablets may include lactose, mannitol, calcium phosphates, magnesium stearate, hydroxypropyl methylcellulose, methyl 10 cellulose, polyvinylpyrrolidone, aluminium silicate, sodium carbonate, potassium phosphate or other suitable materials.

Alternatively, the formulation comprising eicosapentaenoic acid or an ester thereof, and a triterpene or an ester thereof, may be administered 15 topically. The formulation to be applied topically may also comprise an occlusive agent, a surfactant system and water.

One or more various solvents that may be present in the topical formulation comprise various short-chain alcohols including, but not 20 limited to, ethyl alcohol, propylene alcohol, Triacetin, hexylen glycol and combinations thereof. The solvent may be present in an amount ranging from about 5.0 to about 30.0 w/w %.

Suitable occlusive agents that may be present in the topical formulation 25 include, but are not limited to, petrolatum, microcrystalline wax, dimethicone, beeswax, mineral oil, squalane, liquid paraffin, shea butter, carnauba wax, SEPIGELO (a blend of isoparaffin/polyacrylamide/laureth-7), and combinations thereof. The occlusive agent may be present in an amount of at least about 10.1 w/w %.

30

Suitable surfactant systems comprise at least one surfactant and exhibits a



HLB value in a range from about 7.0 to about 10.9. The surfactant system may be present in the formulation in an amount ranging from about 0.25 to about 10.0 w/w%. Suitable surfactants include, but are not limited to, CETOMACROGOLO 1000, (Croder, Inc.) glycerol monostearate, glycerol distearate, glyceryl stearate, polyoxyethylene stearate, a blend of glyceryl stearate and PEG-100 stearate (as ARLACEL 165), polysorbate 40, polysorbate 60, polysorbate 80, CETETH-200, sorbitan monopalimate, sorbitan monostearate, sorbitan monooleate, and combinations thereof.

10

The topical formulation may also include a carrier, a skin conditioner, a preservative, a buffer, a fragrance, water or combinations thereof.

Accordingly to another aspect the invention provides a method for the treatment of various physiological and disease states including rheumatoid arthritis, osteoarthritis, back-ache, psoriasis, pre-menstrual syndrome, bacterial infections, viral infections, fatigue, such as chronic fatigue syndrome, insomnia, anxiety, obesity, influenza, diabetes mellitus, alcoholism, cancer, neurological disorders such as multiple sclerosis, epilepsy, tardive dyskinesia and choreiform disorders such as Huntington's disease, psychiatric disorders such as depression and attention-deficit/hyperactivity disorder, cardiovascular disorders such as hyperlipidemia and high blood pressure, dermatological disorders such as eczema and atopic dermatitis, respiratory disorders, learning disability and ageing, in a subject comprising administering to the subject an effective amount of a formulation comprising eicosapentaenoic acid or an ester thereof, and a triterpene or an ester thereof.

According to a further aspect the invention provides a formulation comprising eicosapentaenoic acid or an ester thereof, and a triterpene or an ester thereof for use in a method of treatment of a human or animal

body by surgery or therapy or of diagnosis practised on the human or animal body.

5 In a further aspect the invention provides the use of eicosapentaenoic acid or an ester thereof, and a triterpene or an ester thereof, in the manufacture or preparation of a medicament for the treatment of various physiological and disease states including rheumatoid arthritis, osteoarthritis, back-ache, psoriasis, pre-menstrual syndrome, bacterial infections, viral infections, fatigue, such as chronic fatigue syndrome, 10 insomnia, anxiety, obesity, influenza, diabetes mellitus, alcoholism, cancer, neurological disorders such as multiple sclerosis, epilepsy, tardive dyskinesia and choreiform disorders such as Huntington's disease, psychiatric disorders such as depression and attention-deficit/hyperactivity disorder, cardiovascular disorders such as 15 hyperlipidemia and high blood pressure, dermatological disorders such as eczema and atopic dermatitis, respiratory disorders, learning disabilities and ageing.

Formulations containing eicosapentaenoic acid or an ester thereof, and a 20 triterpene or an ester thereof, may be used in cosmetic treatments. The cosmetic treatment may have an anti-ageing effect or to reverse the process of ageing.

Preferably the formulation comprises eicosapentaenoic acid or an ester 25 thereof, and a triterpene or an ester thereof in a cosmetically acceptable form.

The cosmetically acceptable formulation may also comprise a cosmetic carrier, diluent or excipient.

According to a yet further aspect the invention provides a method of cosmetic treatment comprising administering an effective amount of a formulation comprising eicosapentaenoic acid or an synthetic ester thereof, and a triterpene or an ester thereof.

5

Preferably, the formulation is administered as an anti-ageing formulation or to reverse the ageing process.

The cosmetic formulation may be administered orally or topically.

10

A yet further aspect of the invention provides a method for preparing a topical formulation comprising mixing eicosapentaenoic acid or an ester thereof and a triterpene or an ester thereof with a topically acceptable carrier.

15

The method may also comprise mixing the eicosapentaenoic acid or an ester thereof and the triterpene or an ester thereof with one or more of the following a solvent, an occlusive agent, a surfactant system and water.

20

The method may also comprise mixing the eicosapentaenoic acid or an ester thereof and the triterpene or an ester thereof with one or more of vitamin E (natural or an analogue), an emulsifying wax, honey, water, fragrance, an emulsifier and a mixture of ethyl, propyl and butyl parabens.

25

A still further aspect of the invention provides a method for preparing an orally administered formulation comprising mixing eicosapentaenoic acid or an ester thereof and a triterpene or an ester thereof with an orally acceptable carrier.

30

The method may also include mixing vitamin E (natural or an analogue) into the formulation. Vitamin E is an antioxidant and thus prevents unwanted oxidation.

- 5 The method may also include adding a flavouring or a taste masking agent to the formulation.

It will be appreciated that the compounds of eicosapentaenoic acid or an ester thereof, and a triterpene or an ester thereof, may be administered  
10 simultaneously, either in the same or different formulations, or sequentially. When there is sequential administration, the delay in administering the second and any subsequent active ingredient should not be such as to lose the beneficial therapeutic or cosmetic effect of the combination. In a preferred aspect of the invention the eicosapentaenoic  
15 acid or an ester thereof, and the triterpene or an ester thereof, are administered in a combined formulation.

According to a further aspect the invention provides a method for the treatment of various physiological and disease states including rheumatoid  
20 arthritis, osteoarthritis, back-ache, psoriasis, pre-menstrual syndrome, bacterial infections, viral infections, fatigue, such as chronic fatigue syndrome, insomnia, anxiety, obesity, influenza, diabetes mellitus, alcoholism, cancer, neurological disorders such as multiple sclerosis, epilepsy, tardive dyskinesia and choreiform disorders such as  
25 Huntington's disease, psychiatric disorders such as depression and attention-deficit/hyperactivity disorder, cardiovascular disorders such as hyperlipidemia and high blood pressure, dermatological disorders such as eczema and atopic dermatitis, respiratory disorders, learning disabilities and ageing, in a subject comprising administering to the subject an  
30 effective amount of eicosapentaenoic acid or an ester thereof, and a triterpene or an ester thereof, wherein the eicosapentaenoic acid, or an

ester thereof, and the triterpene, or an ester thereof, are administered simultaneously, either in the same or different formulations, or sequentially.

- 5 According to a yet further aspect the invention provides the use of eicosapentaenoic acid or an ester thereof, and a triterpene or an ester thereof, administered simultaneously, either in the same or different formulations, or sequentially, in a method of treatment of a human or animal body by surgery or therapy or of diagnosis practised on the human  
10 or animal body.

The present invention will now be illustrated, merely by way of example, with reference to the following methods and examples.

15 **Method of extracting eicosapentaenoic acid and triterpenes**

A method of extracting eicosapentaenoic acid from fish oil is described in Enzyme Microb Technol. 2000 Apr 1;26(7):516-529.

- 20 A method of extracting triterpenes from marigolds is described in Fitoterapia. 2003 Jun; 74(4):328-38. More specifically this paper discloses a method for the purification of the triterpenoid esters faradiol 3-O-laurate, palmitate and myristate from the flower heads of the medicinal plant *Calendula officinalis* (marigold).

25 **Method of preparing a cream formulation for topical administration**

A method for the preparation of a cream for topical application comprising eicosapentaenoic acid and a triterpene comprises placing the following components in a receptacle at room temperature:

- 122 g pure eicosapentaenoic acid;
- 20 g pure gamma-linolenic acid;
- 65 g organic, virgin, cold-pressed, non-raffinated evening primrose oil (which provides the triterpene);
- 5 • 3.4 g D alpha tocopheryl acetate;
- 180 g emulsifying wax; and
- 48 g clear honey.

The components are stirred together and then heated for one minute.

10

To this mixture is then added:

- 540 g water;
- 1.5 g fragrance (e.g. citrus: lime or lemon);
- 15 • 12 g of an emulsifier (to form a stable emulsion); and
- 30 g of a mixture of ethyl, propyl and butyl parabens.

The whole mixture is then gently stirred and heated for a further four minutes. It is then stirred slowly for a further five minutes until it has the  
20 required consistency for the cream. It is then transferred into glass jars that have been sterilized (at over 100 degrees C) using implements that have also been sterilized. Finally, lids that have also been sterilized are fastened on to the jars, which are then left to cool.

## 25 Method of preparing a formulation for oral administration

A method for the preparation of a formulation for oral administration containing eicosapentaenoic acid or a synthetic ester thereof, and a triterpene or a synthetic ester thereof, comprises placing the following  
30 components in a mixing bowl and manually mixing together for five minutes:

- pure eicosapentaenoic acid;
  - pure gamma-linolenic acid;
  - organic, virgin, cold-pressed, non-raffinated evening primrose oil;
  - 5        and
  - D alpha tocopheryl acetate;
- in a ratio, by mass, of 186 to 20 to 50 to 3.2.

10    **Case studies on the use of a cream made according to the above described method**

A number of studies have been undertaken to demonstrate the therapeutic and cosmetic effects of the cream made by the above-described method.

15    **More specifically:**

Cosmetic effect - Anti-ageing

20    Four subjects have thus far specifically used the cream made by the above-described method for its anti-ageing properties.

- Subject 1 - A female, aged 50, used the cream topically on her face and observed that within one week her skin looked younger and 'healthier, fresher, with a radiant look'. She described the cream as being far better than anything she has ever bought (e.g. evening primrose cream). She had sensitive skin, and noticed no adverse side-effects at all.
- 25    • Subject 2 - a female, aged 20, used the cream topically on her face, she also had sensitive skin, and again noticed within one week no adverse side-effects at all. She described her skin as
- 30    looking healthier.

- Subject 3 - a female, aged 51, used the cream topically on her face, this subject derived similar benefits to subject 1, and described the result as being similar to 'botox without needles'.
- Subject 4 - a male aged 52, used the cream topically on his face, the subject described the effects within one week as being 'like a face-lift without surgery'.

All four subjects asked to continue applying the cream to their faces. The female subjects wish to use it instead of a traditional cosmetic foundation application.

These initial test results demonstrate the anti-ageing cosmetic effect of a cream according to the present invention.

#### Therapeutic effect - Back-ache

A female subject aged 75 with previously intractable back-ache began to derive relief of her back pain after three days' topical application of a cream made by the above-described method.

#### Therapeutic Effect - Arthritis

- Subject 1 - A female aged 69 suffering from severe rheumatoid arthritis in her hands, which had not responded to traditional medical treatment, applied cream made by the above-described method to her hands and an improvement was seen within one week.
- Subject 2 - An 89-year-old female with severe osteoarthritis in the hands, which had never previously responded to any treatment, showed improvement after one week when applying cream, made



by the above-described method, to her hands. The improvements observed included relief from the pain, for the first time, and a decrease in the size of tophi (swellings).

5    Therapeutic/Cosmetic effect - Skin sores

A 69-year-old female subject with severe rheumatoid arthritis (see above) also noticed that her skin sores on her hands were much better seven to eight days after beginning use of the cream made by the above-described  
10    method. They had previously failed to respond to medical treatment and had had to be bandaged.

Therapeutic effect - Psoriasis

15

- Subject 1 - A female aged 17 with severe intractable treatment-resistant psoriasis started to improve after two to three days following topical application of cream, made by the above-described method, to her arms and legs.
- 20    •    Subject 2 - A female aged 31 with severe psoriasis affecting her upper limbs responded after six to seven days when applying the cream, made by the above-described method, to her upper limbs; she had previously tried a wide range of medical and 'alternative' treatments, to no avail.

25

Therapeutic/Cosmetic effect - Eczema

A 52-year-old female subject with severe eczema responded within one  
30    week to the topical application of cream, made by the above-described

method, again where conventional medical treatment had previously failed.

Oral Administration - Learning Difficulties

5

An 11-year-old boy with learning difficulties started taking 1.5 g daily of the oral formulation discussed above. Within four weeks he started to show signs of improvement according to his parents and teachers. This improvement was in several domains, including cognitive functioning, reading and understanding his school work. The improvement continued and he reached a new, higher, level of intellectual functioning after three months, which has continued to be sustained for 6 months.

10

## CLAIMS

1. A formulation comprising:  
(a) eicosapentaenoic acid or an ester thereof; and  
(b) a triterpene or an ester thereof.
- 5 2. A formulation according to claim 1 in which the eicosapentaenoic acid or ester thereof is selected from the group comprising natural eicosapentaenoic acids, synthetic eicosapentaenoic acids, naturally occurring esters of eicosapentaenoic acids, synthetic esters of  
10 eicosapentaenoic acids, and combinations thereof.
3. A formulation according to claim 1 or claim 2 in which the triterpene or ester thereof is selected from the group comprising naturally occurring triterpenes, synthetic triterpenes, naturally  
15 occurring esters of a triterpene, and synthetic esters of a triterpene, and combinations thereof.
4. A formulation according to claim 3 in which the triterpene is selected from the group comprising 3-*O*-trans caffeoyl derivatives  
20 of betulinic acid, morolic acid or oleanolic acid, faradiol-*O*-laurate, faradiol-*O*-palmitate and faradiol-*O*-myristate.
5. A formulation according to any of claims 1 to 3 in which the triterpene is isolated from the flower heads of marigolds  
25 (*Calendula officinalis*), *Zygophyllum eichwaldii*, *Carthamus lanatus*, *Oenothera bienni* (evening primrose) or *Pyrus comminus*.
6. A formulation according to any preceding claim comprising up to  
30 99% w/w of eicosapentaenoic acid or an ester thereof.

7. A formulation according to claim 6 comprising up to 50% w/w of eicosapentaenoic acid or an ester thereof.
8. A formulation according to any preceding claim comprising up to 99% w/w of triterpene or an ester thereof.
9. A formulation according to claim 8 comprising up to 50% w/w of triterpene or an ester thereof.
10. A formulation according to claim 6 comprising up to 70% w/w of eicosapentaenoic acid or an ester thereof and from 1 to 30% w/w of a triterpene or an ester thereof.
11. A formulation according to any preceding claim in a pharmaceutically acceptable form.
12. A formulation according to any preceding claim comprising a pharmaceutical carrier, diluent or excipient.
13. A formulation according to any preceding claim comprising one or more components selected from lubricants, flavourings, taste masking agents, fragrances and preservatives.
14. A formulation according to any preceding claim comprising other compounds for co-administration.
15. A formulation according to claim 14 in which the compound is gamma-linolenic acid or docosahexaenoic acid.
16. A formulation according to any of the preceding claims which does not include docosahexaenoic acid.

17. Use of a formulation according to any preceding claim in the treatment of physiological and disease states selected from the group comprising rheumatoid arthritis, osteoarthritis, back-ache, psoriasis, pre-menstrual syndrome, bacterial infections, viral infections, fatigue, insomnia, anxiety, obesity, influenza, diabetes mellitus, alcoholism, cancer, neurological disorders, epilepsy, tardive dyskinesia and choreiform disorders, psychiatric disorders, cardiovascular disorders, dermatological disorders, respiratory disorders, learning disabilities and ageing.
18. A liquid, a paste, a tablet or a capsule for oral administration comprising the formulation of any one of claims 1 to 16.
19. An inert porous matrix tablet comprising a formulation according to any one of claims 1 to 16 also comprising waxes or water insoluble polymers and fillers and binders.
20. A tablet according to claim 19 also comprising a diffusion retarding compound selected from the group comprising paraffin, polyvinylchloride, ethylcellulose, stearic alcohol, cetyl alcohol, carnauba wax, polyethylene, polyvinyl acetate and polymethyl methacrylate.
21. A tablet according to claim 19 or 20 comprising other excipients selected from lactose, mannitol, calcium phosphates, magnesium stearate, hydroxypropyl methylcellulose, methyl cellulose, polyvinylpyrrolidone, aluminium silicate, sodium carbonate, potassium phosphate and other suitable materials.

22. A compound for topical application comprising a formulation according to any one of claims 1 to 16.
- 5 23. A compound according to claim 22 also comprising one or more components selected from occlusive agents, surfactant systems and water.
24. A compound according to claim 22 or 23 comprising one or more solvents.
- 10 25. A compound according to claim 24 in which the solvent is a short-chain alcohol.
- 15 26. A compound according to claim 24 or 25 in which the solvent is present in an amount ranging from about 5.0 to about 30.0 w/w %.
- 20 27. A compound according to claim 23 in which the occlusive agent is selected from the group comprising petrolatum, microcrystalline wax, dimethicone, beeswax, mineral oil, squalane, liquid paraffin, shea butter, carnauba wax, a blend of isoparaffin/polyacrylamide/laureth-7, and combinations thereof.
- 25 28. A compound according to claim 23 or 28 in which the occlusive agent is present in an amount of about 0.1 w/w % or more.
29. A compound according to claim 23 in which the surfactant system exhibits a HLB value in a range from about 7.0 to about 10.9.
- 30 30. A compound according to claim 23 or claim 29 in which the surfactant is selected from the group comprising CETOMACROGOLO 1000, (Crodor, Inc.) glycerol monostearate,

glycerol distearate, glyceryl stearate, polyoxyethylene stearate, a blend of glyceryl stearate and PEG-100 stearate (as ARLACEL 165), polysorbate 40, polysorbate 60, polysorbate 80, CETETH-200, sorbitan monopalimate, sorbitan monostearate, sorbitan monooleate, and combinations thereof.

5

31. A compound according to any of claims 22 to 30 comprising one or more components selected from carriers, skin conditioners, preservatives, buffers, fragrances, and water.

10

32. A method for the treatment of physiological and disease states including rheumatoid arthritis, osteoarthritis, back-ache, psoriasis, pre-menstrual syndrome, bacterial infections, viral infections, fatigue, insomnia, anxiety, obesity, influenza, diabetes mellitus, alcoholism, cancer, neurological disorders, epilepsy, tardive dyskinesia and choreiform disorders, psychiatric disorders, cardiovascular disorders, dermatological disorders, respiratory disorders, learning disability and ageing, in a subject comprising administering to the subject, an effective amount of a formulation comprising eicosapentaenoic acid or an ester thereof, and a triterpene or an ester thereof.

15

20

25

33. The method of claim 32, wherein the eicosapentaenoic acid, or an ester thereof, and the triterpene, or an ester thereof, are administered simultaneously, either in the same or different formulations, or sequentially

30

34. A formulation comprising eicosapentaenoic acid or an ester thereof, and a triterpene or an ester thereof for use in a method of treatment of a human or animal body by surgery or therapy or of diagnosis practised on the human or animal body.

35. The use of eicosapentaenoic acid or an ester thereof, and a triterpene or an ester thereof, in the manufacture or preparation of a medicament for the treatment of physiological and disease states including rheumatoid arthritis, osteoarthritis, back-ache, psoriasis, pre-menstrual syndrome, bacterial infections, viral infections, fatigue, insomnia, anxiety, obesity, influenza, diabetes mellitus, alcoholism, cancer, neurological disorders, epilepsy, tardive dyskinesia and choreiform disorders, psychiatric disorders, cardiovascular disorders, dermatological disorders, respiratory disorders, learning disabilities and ageing.
36. The use of a formulation according to any of claims 1 to 16 in cosmetic treatment.
37. The use of claim 16 to have an anti-ageing effect or to reverse the process of ageing.
38. The formulation according to any of claims 1 to 16 in a cosmetically acceptable form.
39. The formulation according to claim 38 comprising a cosmetically acceptable carrier, diluent or excipient.
40. A formulation according to claim 37, 38 or 39 for oral or topical administration.
41. A method of cosmetic treatment comprising administering an effective amount of a formulation comprising eicosapentaenoic acid or an ester thereof, and a triterpene or an ester thereof.



42. A method for preparing a topical formulation comprising mixing eicosapentaenoic acid or an ester thereof and a triterpene or an ester thereof with a topically acceptable carrier.
- 5 43. A method according to claim 42 comprising mixing the eicosapentaenoic acid or an ester thereof and the triterpene or an ester thereof with one or more component selected from solvents, occlusive agents, surfactant systems and water.
- 10 44. A method according to claim 42 or 43 comprising mixing the eicosapentaenoic acid or an ester thereof and the triterpene or an ester thereof with one or more component selected from vitamin E (natural or an analogue), emulsifying waxes, honey, water, fragrances, emulsifiers and mixtures of ethyl, propyl and butyl parabens.
- 15
45. A method for preparing an orally administered formulation comprising mixing eicosapentaenoic acid or an ester thereof and a triterpene or an ester thereof with an orally acceptable carrier.
- 20
46. A method according to claim 45 including mixing vitamin E (natural or an analogue) into the formulation.
47. A method according to claim 45 or 46 including adding a flavouring or a taste masking agent to the formulation.
- 25
48. The use of eicosapentaenoic acid or an ester thereof, and a triterpene or an ester thereof, administered simultaneously, either in the same or different formulations, or sequentially, or separately, in a method of treatment of a human or animal body by
- 30

surgery or therapy or of diagnosis practised on the human or animal body.



PCT/GB2004/005461

